Jefferies Financial Group Issues Pessimistic Forecast for Inspire Medical Systems (NYSE:INSP) Stock Price

Inspire Medical Systems (NYSE:INSP) had its price target reduced by analysts at Jefferies Financial Group from $81.00 to $66.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has a “hold” rating on the stock. Jefferies Financial Group’s target price would suggest a potential upside of 10.40% from the company’s current price.

Several other research analysts have also recently issued reports on the company. UBS Group set a $96.00 target price on Inspire Medical Systems in a research report on Thursday, January 22nd. KeyCorp restated a “sector weight” rating on shares of Inspire Medical Systems in a research note on Tuesday, November 4th. Morgan Stanley reiterated an “equal weight” rating and issued a $130.00 target price (up previously from $105.00) on shares of Inspire Medical Systems in a research note on Tuesday, December 2nd. Piper Sandler lowered their target price on shares of Inspire Medical Systems from $165.00 to $85.00 and set an “overweight” rating for the company in a report on Thursday. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Inspire Medical Systems in a report on Monday, December 29th. Five research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $108.94.

Inspire Medical Systems Price Performance

INSP opened at $59.78 on Thursday. Inspire Medical Systems has a fifty-two week low of $53.11 and a fifty-two week high of $197.75. The firm has a market capitalization of $1.74 billion, a PE ratio of 12.00, a P/E/G ratio of 6.34 and a beta of 0.74. The company’s 50-day moving average is $92.88 and its 200 day moving average is $90.99.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings results on Wednesday, February 11th. The company reported $1.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.96. The business had revenue of $269.08 million during the quarter, compared to the consensus estimate of $264.02 million. Inspire Medical Systems had a return on equity of 10.96% and a net margin of 15.95%.The company’s quarterly revenue was up 12.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.15 EPS. As a group, analysts expect that Inspire Medical Systems will post 2.16 EPS for the current year.

Insider Activity at Inspire Medical Systems

In related news, Director Shawn Mccormick sold 2,000 shares of the business’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $127.48, for a total value of $254,960.00. Following the transaction, the director directly owned 26,046 shares of the company’s stock, valued at approximately $3,320,344.08. The trade was a 7.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.10% of the stock is owned by insiders.

Institutional Trading of Inspire Medical Systems

Large investors have recently added to or reduced their stakes in the stock. Dragoneer Investment Group LLC raised its position in Inspire Medical Systems by 81.4% in the second quarter. Dragoneer Investment Group LLC now owns 2,354,411 shares of the company’s stock worth $305,532,000 after acquiring an additional 1,056,808 shares during the period. Wasatch Advisors LP increased its stake in shares of Inspire Medical Systems by 7.2% during the 2nd quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company’s stock worth $212,095,000 after purchasing an additional 110,288 shares during the last quarter. William Blair Investment Management LLC increased its stake in shares of Inspire Medical Systems by 68.7% during the 3rd quarter. William Blair Investment Management LLC now owns 1,297,573 shares of the company’s stock worth $96,280,000 after purchasing an additional 528,404 shares during the last quarter. Morgan Stanley raised its holdings in shares of Inspire Medical Systems by 179.5% in the 4th quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock worth $116,188,000 after purchasing an additional 809,121 shares during the period. Finally, Deerfield Management Company L.P. lifted its stake in Inspire Medical Systems by 648.4% in the third quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock valued at $77,739,000 after purchasing an additional 907,694 shares during the last quarter. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Key Headlines Impacting Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q4 beat: INSP reported $1.65 EPS vs. $0.69 expected and revenue of ~$269M, with expanded gross margins — a near-term operational positive. Zacks: INSP Beats Q4 Estimates
• Positive Sentiment: Some firms remain constructive at reduced targets — Mizuho and Piper Sandler kept outperform/overweight stances after lowering PTs, signaling there’s still perceived upside if reimbursement issues resolve. The Fly: Mizuho PT Cut
• Neutral Sentiment: Earnings call materials and transcript are available for detailed read-through (management commentary on coding, reimbursement and 2026 guide are key). Review to judge whether guidance risks are transitory. Seeking Alpha: Q4 Earnings Call Transcript
• Negative Sentiment: Management issued a 2026 revenue outlook of $950M–$1B and flagged a coding change plus reimbursement headwinds — the primary catalyst for the selloff risk and weaker forward expectations. MSN: 2026 Revenue Outlook & Coding Change
• Negative Sentiment: Multiple analyst downgrades and price-target cuts (Wells Fargo, Baird, Jefferies, Truist and others) followed the guidance and reimbursement concerns, increasing near-term selling pressure. Investing.com: Baird, Wells Fargo Cuts
• Negative Sentiment: The stock already experienced an earlier ~8% intraday decline after the coding/guidance news, showing how sensitive the market is to reimbursement updates. Investing.com: Shares Slide 8%

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.